Please login to the form below

Not currently logged in
Email:
Password:

OSE Immunotherapeutics

This page shows the latest OSE Immunotherapeutics news and features for those working in and with pharma, biotech and healthcare.

Boehringer builds in immuno-oncology with €1.1bn-plus OSE deal

Boehringer builds in immuno-oncology with €1.1bn-plus OSE deal

Boehringer Ingelheim has licensed a new checkpoint inhibitor from French biotech OSE Immunotherapeutics in a deal that could be worth more than 1.1bn (around $1.4bn). ... The deal focuses around OSE-172, an anti-SIRP-alpha antibody with potential in

Latest news

More from news
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Iris Pauporté joins OSE Immunotherapeutics Iris Pauporté joins OSE Immunotherapeutics

    Iris Pauporté joins OSE Immunotherapeutics. She becomes clinical project director at the French biotech. ... Alain Chatelin, medical director at OSE Immunotherapeutics, said: “ We are very pleased to have Iris join our team. “

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics